Scilex Holding Company
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Henry H. Ji
- Full Time Employees
- 34
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 960 San Antonio Road Palo Alto CA United States of America 94303
- IPO Date
- Mar 5, 2021
- CIK
- 0001820190
- Website
- scilexholding.com
- Similar Companies
- Business
- Scilex Holding Company is a biopharmaceutical firm focused on the acquisition, development, and commercialization of non-opioid solutions for acute and chronic pain management, alongside potential expansion into neurodegenerative and cardiometabolic diseases through a proposed joint venture. The company's portfolio features several marketed products, including ZTlido 1.8%, a prescription topical lidocaine system addressing neuropathic discomfort linked to post-herpetic neuralgia, a condition stemming from shingles. Additionally, its commercial offerings extend to ELYXYB, an oral solution approved for the acute treatment of migraine attacks in adults, and GLOPERBA, a liquid oral version of colchicine used to prevent painful gout flares. The pipeline features advanced candidates such as SP-102 (SEMDEXA), a specialized viscous gel formulation of a corticosteroid for epidural injections, which has completed a Phase 3 study targeting lumbosacral radicular pain or sciatica and holds FDA Fast Track status. Also in development are SP-103, a next-generation topical lidocaine system that has completed Phase 2 trials for chronic neck and low back pain, and SP-104, a novel low-dose naltrexone hydrochloride formulation that has completed Phase 1 for fibromyalgia treatment. Headquartered in Palo Alto, California, Scilex Holding Company has recently engaged in strategic initiatives, including a substantial Bitcoin investment in Datavault AI Inc. and an exclusive licensing agreement for an AI-driven biotech exchange platform. The company continues to operate as a majority-owned subsidiary of Sorrento Therapeutics, Inc.
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026
Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
Scilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
Wellgistics Health and Datavault AI to Form DelivMeds AI via PharmacyChain™ License Expansion and Acquisitions of QOLPOM Biometric Health Data and Drone Logistics IP and Majority of Tollo Health
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026
Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform
Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform
Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026
Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd.
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026
Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets
Scilex (NASDAQ:SCLX) Trading Up 8.8% – Time to Buy?